Compass Therapeutics Management
Management criteria checks 0/4
Compass Therapeutics' CEO is Tom Schuetz, appointed in May 2024, has a tenure of less than a year. total yearly compensation is $4.87M, comprised of 11.8% salary and 88.2% bonuses, including company stock and options. directly owns 3.82% of the company’s shares, worth $8.36M. The average tenure of the management team and the board of directors is 1.2 years and 2.7 years respectively.
Key information
Tom Schuetz
Chief executive officer
US$4.9m
Total compensation
CEO salary percentage | 11.8% |
CEO tenure | less than a year |
CEO ownership | 3.8% |
Management average tenure | 1.2yrs |
Board average tenure | 2.7yrs |
Recent management updates
Recent updates
We Think Compass Therapeutics (NASDAQ:CMPX) Can Afford To Drive Business Growth
Jun 05We're Hopeful That Compass Therapeutics (NASDAQ:CMPX) Will Use Its Cash Wisely
Feb 13Companies Like Compass Therapeutics (NASDAQ:CMPX) Are In A Position To Invest In Growth
Sep 20Compass Therapeutics, Merck ink collaboration deal for early-stage cancer trial
Oct 11CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Jun 30 2024 | n/a | n/a | -US$47m |
Mar 31 2024 | n/a | n/a | -US$45m |
Dec 31 2023 | US$5m | US$575k | -US$42m |
Sep 30 2023 | n/a | n/a | -US$41m |
Jun 30 2023 | n/a | n/a | -US$43m |
Mar 31 2023 | n/a | n/a | -US$40m |
Dec 31 2022 | US$2m | US$550k | -US$39m |
Sep 30 2022 | n/a | n/a | -US$41m |
Jun 30 2022 | n/a | n/a | -US$35m |
Mar 31 2022 | n/a | n/a | -US$82m |
Dec 31 2021 | US$5m | US$4k | -US$82m |
Sep 30 2021 | n/a | n/a | -US$78m |
Jun 30 2021 | n/a | n/a | -US$81m |
Mar 31 2021 | n/a | n/a | -US$31m |
Dec 31 2020 | US$3m | US$4k | -US$29m |
Sep 30 2020 | n/a | n/a | -US$28m |
Jun 30 2020 | n/a | n/a | -US$27m |
Mar 31 2020 | n/a | n/a | -US$30m |
Dec 31 2019 | US$1m | US$400k | -US$35m |
Compensation vs Market: Tom's total compensation ($USD4.87M) is above average for companies of similar size in the US market ($USD1.46M).
Compensation vs Earnings: Tom's compensation has increased whilst the company is unprofitable.
CEO
Tom Schuetz (63 yo)
less than a year
Tenure
US$4,873,206
Compensation
Dr. Thomas J. Schuetz, also known as Tom, M.D., Ph.D. was co-founded of Compass Therapeutics, Inc in 2014 until 2024 and He serves as its CEO since May 28, 2024. He also served as President since May 28, 2...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Chief Executive Officer | less than a year | US$4.87m | 3.82% $ 8.4m | |
Senior Consultant | less than a year | US$4.07m | 0.56% $ 1.2m | |
Vice President of Finance | no data | no data | no data | |
VP, Head of Legal & Corporate Secretary | 3.1yrs | no data | 0.00073% $ 1.6k | |
Communications Manager | no data | no data | no data | |
Senior VP & Head of Clinical Development | 1.3yrs | no data | no data | |
VP & Head of Clinical Operations | 1.3yrs | no data | no data | |
VP and Head of Chemistry Manufacturing & Controls | 1.1yrs | no data | no data |
1.2yrs
Average Tenure
59yo
Average Age
Experienced Management: CMPX's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Independent Chairman | 9.7yrs | US$222.63k | 0% $ 0 | |
Member of Clinical Advisory Board | 2.7yrs | no data | no data | |
Independent Director | 2.4yrs | US$163.42k | 0% $ 0 | |
Independent Director | 9.7yrs | US$193.02k | 0% $ 0 | |
Independent Director | 1.4yrs | US$147.92k | 0% $ 0 | |
Independent Director | 2.4yrs | US$163.42k | 0% $ 0 | |
Independent Director | 1.8yrs | US$45.00k | 0% $ 0 | |
Member of Clinical Advisory Board | 4.9yrs | no data | no data | |
Member of Clinical Advisory Board | 2.7yrs | no data | no data | |
Member of Clinical Advisory Board | 2.7yrs | no data | no data | |
Member of Clinical Advisory Board | 2.7yrs | no data | no data |
2.7yrs
Average Tenure
62yo
Average Age
Experienced Board: CMPX's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.